Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptevo Therapeutics Inc APVO

Healthcare Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and... see more

Recent & Breaking News (NDAQ:APVO)

Aptevo Therapeutics Reports Third Quarter 2017 Financial Results

GlobeNewswire November 9, 2017

Aptevo Therapeutics Presents New Preclinical Data on APVO436 – a Next Generation ADAPTIR™ Bispecific Antibody Candidate

GlobeNewswire October 30, 2017

Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 – a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics

GlobeNewswire October 24, 2017

Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting

GlobeNewswire October 16, 2017

Mid-Day Market Update: Onvia Climbs On Acquisition News; Intellicheck Shares Plummet

Benzinga.com  October 5, 2017

Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR™ Bispecific Platform at the World Bispecific Summit

GlobeNewswire October 2, 2017

Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial

GlobeNewswire September 28, 2017

Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million

GlobeNewswire September 28, 2017

Mid-Day Market Update: Palo Alto Networks Surges After Strong Q4 Results; Ambarella Shares Plunge

Benzinga.com  September 1, 2017

Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products

GlobeNewswire August 31, 2017

Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414

GlobeNewswire August 31, 2017

Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527

GlobeNewswire August 17, 2017

Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy

GlobeNewswire July 20, 2017

Aptevo Therapeutics Highlights Key Features of Its ADAPTIR™ Protein Therapeutic Platform at Two Industry Conferences

GlobeNewswire June 7, 2017

Aptevo Therapeutics Reports First Quarter 2017 Financial Results

GlobeNewswire May 12, 2017

Aptevo Therapeutics Presents Detailed Overview of its Adaptir™ Protein Therapeutic Platform at the 13th Annual Pegs Summit

GlobeNewswire May 5, 2017

Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B

GlobeNewswire April 10, 2017

Aptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation

GlobeNewswire April 3, 2017

Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update

GlobeNewswire March 31, 2017

Aptevo Therapeutics Announces New IXINITY Supply Available May 2017

GlobeNewswire March 15, 2017